RESUMEN
Granular activated carbon (GAC) and ion exchange resin (IXR) are widely used as adsorbents to remove PFAS from drinking water sources and effluent waste streams. However, the high cost associated with GAC and IXR generation has motivated the development of less expensive adsorbents for treatment of PFAS-impacted water. Thus, the objective of this research was to create an economically viable and sustainable PFAS adsorbent from sewage sludge. Stepwise pyrolysis at temperatures from 300 °C to 1000 °C yielded biochars whose specific surface area (SSA) and porosity increased from 41 to 148 m2/g, and from 0.062 to 0.193 cm3/g, respectively. On a per organic char basis, the SSA of the biochar was as high as 1183 m2/g, which is comparable to commercially-available activated carbons. The adsorption of perfluorooctane sulfonic acid (PFOS) on sludge biochar increased with increasing pyrolysis temperature, which was positively correlated with increasing porosity and SSA. When 1000 °C processed biochar was tested with a mixture of eight PFAS, preferential adsorption of longer carbon chain-length species was observed, indicating the importance of PFAS hydrophobic interactions with the biochar and the availability of a wide range of mesopores. The adsorption of each PFAS was dependent upon both chain length and head group, with longer chain-length species exhibiting greater adsorption than shorter chain-length species, along with greater adsorption of species with sulfonic acid head groups compared to their chain length counterparts with carboxylic acid head groups. These findings demonstrate that biochar derived from municipal solid waste can serve as a cost-effective and sustainable adsorbent for the removal of PFOS and PFAS mixtures from source waters. The circular economy benefits and waste reduction potential associated with the use of sewage sludge-derived biochar supports the development of a viable sludge-derived biochar for the removal of PFAS from water.
RESUMEN
The prevention of musculoskeletal injuries and their related welfare and economic impacts represent an immediate priority for the horse racing industry. This prospective pilot study aimed to evaluate a method to quantitatively analyze scintigraphic features of specific anatomical regions of the horse's appendicular skeleton in combination with secondary measures of musculoskeletal metabolism in blood. Twelve horses referred for scintigraphic assessment of lameness were enrolled. Blood samples were collected immediately prior to the administration of radiotracer. Serum concentrations associated with bone turnover were determined for the following biomarkers: C-terminal telopeptides of type I collagen, proteoglycans and sulfated glycosaminoglycans, collagen type II, osteocalcin, and procollagen II C-terminal propeptide. Scintigraphic images underwent radiomic analysis of discrete regions of the distal limbs and these data were correlated to bone turnover markers. Three lame horses demonstrated asymmetrical radiomic abnormalities. The concentration of osteocalcin in the lame horses was significantly higher when compared to the control group, while no significant changes were observed for the other screened serum biomarkers. Findings from the current study provided evidence that radiomic analysis of equine scintigraphy is feasible. This method has the potential to interrogate which serum markers are associated with musculoskeletal injuries.
Asunto(s)
Huesos , Caballos , Animales , Proyectos Piloto , Osteocalcina , Estudios Prospectivos , Huesos/diagnóstico por imagen , Biomarcadores/metabolismoRESUMEN
The adsorption of serum proteins on the surface of nanoparticles (NPs) delivered into a biological environment has been known to alter NP surface properties and consequently their targeting efficiency. In this paper, we use random copolymer (p(HEMA- ran-GMA))-based NPs synthesized using 2-hydroxyethyl methacrylate (HEMA) and glycidyl methacrylate (GMA). We show that serum proteins bind to the NP and that functionalization with antibodies and peptides designed to facilitate NP passage across the blood-brain barrier (BBB) to bind specific cell types is ineffective. In particular, we use systematic in vitro and in vivo analyses to demonstrate that p(HEMA- ran-GMA) NPs functionalized with HIV-1 trans-activating transcriptor peptide (known to cross the BBB) and α neural/glial antigen 2 (NG2) (known for targeting oligodendrocyte precursor cells (OPCs)), individually and in combination, do not specifically target OPCs and are unable to cross the BBB, likely due to the serum protein binding to the NPs.
Asunto(s)
Barrera Hematoencefálica/metabolismo , Nanopartículas/química , Nanopartículas/metabolismo , Animales , Transporte Biológico/fisiología , Compuestos Epoxi/química , Femenino , Masculino , Metacrilatos/química , Microscopía Confocal , Células Precursoras de Oligodendrocitos/metabolismo , Polímeros/química , RatasRESUMEN
Following injury to the central nervous system, secondary degeneration is mediated by Ca2+ imbalances and overproduction of reactive oxygen species from mitochondria, and is associated with myelin deficits and loss of function. Preventing intracellular Ca2+ influx at the acute phase of injury is a potential strategy for limiting these deficits and preserving function. The use of single ion channel inhibitors has had little success in attenuating morphological and functional deficits, potentially due to the many pathways by which calcium can traverse the cell membrane. Focus has shifted to the simultaneous administration of a combination of ion channel inhibitors: lomerizine, oxATP, and YM872. The combination has resulted in reductions in oxidative damage, as well as preservation of function and myelin ultrastructure, potentially due to the protection of oligodendrocytes and their progenitors. The use of multiple ion channel inhibitors is promising and suggests a reduction in total intracellular Ca2+ influx is necessary and sufficient for the protection of neurons and glia following neurotrauma. Optimization of treatment timing, inhibitor choice, and method of delivery will be required for translation of this strategy to the clinic.